Citizens JMP’s $6 target on PRLD

PRLD Prelude Therapeutics

$3.56 → $6 (+69%) by Oct 2027

Market Outperform · reiterates · said Oct 14, 2026 · 12-month default horizon

Open: judged on the close on Oct 14, 2027

The article this target came from

Citizens reiterates Prelude Therapeutics stock rating on Lilly deal

Investing.com · Oct 14, 2026

Citizens reiterated a Market Outperform rating and $6.00 price target on Prelude Therapeutics

Citizens JMP’s track record → Prelude Therapeutics →

A fact about what Citizens JMP published, as reported by Investing.com, not a recommendation from Dalsna Finance; Citizens JMP is not affiliated with this site.

Full methodology: how targets are collected, scored, ranked and corrected, what each field means, and how to cite the data.